Tests JAB-8263 in adults with active rheumatoid arthritis
Tests the drug JAB-8263 in adults with active rheumatoid arthritis, a joint disease.
Plain-language title generated from the registry record
Registry title: A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07684157, who can take part
Where in China
- Beijing HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jacobio Pharmaceuticals Co., Ltd.
- Trial code
- NCT07684157
- Record updated
- 28 September 2026
- Original description
This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.Read full original descriptionShow less
A Phase IIa Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JAB-8263 in Patients With Active Rheumatoid Arthritis
This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.
Inclusion: Age ≥18 years old and <75 years old at the time of signing the informed consent form, regardless of gender; Active rheumatoid arthritis, ESR or C-reactive protein> upper limit of normal; Meets the 2010 American College of Rheumatology ACR/EULAR RA classification standards; Participants have recovered from adverse reactions to previous antirheumatic treatment.
Exclusion: Use of topical glucocorticoids within 2 weeks before the first dose of investigational product or have received epidural, intraarticular, intramuscular, oral or intravenous glucocorticoids within 4 weeks, and do not use adrenocorticotropin; Use of NSAIDs within 1 week before first dose of investigational product; Known or suspected allergies to the investigational product or any of its components; Have evidence of active tuberculosis (TB) or have previously had evidence of active TB and have not received appropriate documented treatment; Current active shingles virus infection, including shingles or herpes simplex types 1 and 2 (confirmed by physical examination and medical history); participants had a history of severe herpes infection, including any disseminated disease, shingles in multiple skin areas, herpes encephalitis, ocular herpes, or recurrent shingles (2 episodes greater than or equal to 2 episodes within 2 years).